Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
NCT ID: NCT01571518
Last Updated: 2012-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2012-04-30
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
NCT02685111
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
NCT03793205
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
NCT03251768
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
NCT00771433
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00770172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
early injection
injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
late leukostim
injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
late injection
injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
early leukostim
injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
late leukostim
injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
early leukostim
injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* cardiovascualr disease,
* abnormal renal function,
* hematologic disorder
20 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A Pharmaceutical Co., Ltd.
INDUSTRY
Hyuk moon Kim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyuk moon Kim
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chul Wan Lim, MD,PhD
Role: STUDY_CHAIR
Soonchunhyang U Puchun Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Soonchunhyang university Puchun Hospital
Puchun, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer. 2011 Apr;19(4):497-504. doi: 10.1007/s00520-010-0843-8. Epub 2010 Mar 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-91
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.